Laurus Labs Limited

NSEI:LAURUSLABS Stock Report

Market Cap: ₹315.0b

Laurus Labs Valuation

Is LAURUSLABS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LAURUSLABS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
₹300.65
Fair Value
94.3% overvalued intrinsic discount
14
Number of Analysts

Below Fair Value: LAURUSLABS (₹584.05) is trading above our estimate of fair value (₹300.65)

Significantly Below Fair Value: LAURUSLABS is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LAURUSLABS?

Key metric: As LAURUSLABS is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for LAURUSLABS. This is calculated by dividing LAURUSLABS's market cap by their current revenue.
What is LAURUSLABS's PS Ratio?
PS Ratio6x
Sales₹52.73b
Market Cap₹314.95b

Price to Sales Ratio vs Peers

How does LAURUSLABS's PS Ratio compare to its peers?

The above table shows the PS ratio for LAURUSLABS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11x
500660 GlaxoSmithKline Pharmaceuticals
9.4x8.8%₹334.8b
PPLPHARMA Piramal Pharma
3.5x14.3%₹308.8b
SUVENPHAR Suven Pharmaceuticals
27.9xn/a₹268.5b
EMCURE Emcure Pharmaceuticals
3.2x11.3%₹232.7b
LAURUSLABS Laurus Labs
6x15.9%₹315.0b

Price-To-Sales vs Peers: LAURUSLABS is good value based on its Price-To-Sales Ratio (6x) compared to the peer average (15.3x).

Price to Sales Ratio vs Industry

How does LAURUSLABS's PS Ratio compare vs other companies in the IN Pharmaceuticals Industry?

16 CompaniesPrice / SalesEstimated GrowthMarket Cap
NECLIFE Nectar Lifesciences
0.5xn/aUS$87.75m
539561 Remedium Lifecare
0.05xn/aUS$20.94m
524824 Bal Pharma
0.6xn/aUS$20.84m
531173 Syschem (India)
0.6xn/aUS$20.33m
LAURUSLABS 6.0xIndustry Avg. 2.8xNo. of Companies24PS02.44.87.29.612+
16 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: LAURUSLABS is expensive based on its Price-To-Sales Ratio (6x) compared to the Indian Pharmaceuticals industry average (2.8x).

Price to Sales Ratio vs Fair Ratio

What is LAURUSLABS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LAURUSLABS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6x
Fair PS Ratio5.6x

Price-To-Sales vs Fair Ratio: LAURUSLABS is expensive based on its Price-To-Sales Ratio (6x) compared to the estimated Fair Price-To-Sales Ratio (5.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LAURUSLABS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹584.05
₹526.50
-9.9%
22.4%₹720.00₹293.00n/a14
Jan ’26₹615.65
₹420.50
-31.7%
21.2%₹531.00₹293.00n/a14
Dec ’25₹567.15
₹420.50
-25.9%
21.2%₹531.00₹293.00n/a14
Nov ’25₹499.80
₹422.47
-15.5%
20.5%₹531.00₹293.00n/a15
Oct ’25₹469.30
₹399.47
-14.9%
21.6%₹516.00₹250.00n/a15
Sep ’25₹470.15
₹399.47
-15.0%
21.6%₹516.00₹250.00n/a15
Aug ’25₹451.75
₹399.47
-11.6%
21.6%₹516.00₹250.00n/a15
Jul ’25₹430.80
₹393.40
-8.7%
21.8%₹503.00₹250.00n/a15
Jun ’25₹418.95
₹383.43
-8.5%
22.0%₹503.00₹250.00n/a14
May ’25₹450.00
₹383.43
-14.8%
22.0%₹503.00₹250.00n/a14
Apr ’25₹405.25
₹369.31
-8.9%
18.3%₹450.00₹250.00n/a13
Mar ’25₹409.80
₹369.31
-9.9%
18.3%₹450.00₹250.00n/a13
Feb ’25₹389.25
₹368.15
-5.4%
18.7%₹450.00₹250.00₹584.0513
Jan ’25₹433.05
₹373.38
-13.8%
21.7%₹490.00₹260.00₹615.6513
Dec ’24₹378.75
₹373.38
-1.4%
21.7%₹490.00₹260.00₹567.1513
Nov ’24₹358.90
₹370.83
+3.3%
22.6%₹490.00₹260.00₹499.8012
Oct ’24₹395.40
₹346.20
-12.4%
19.2%₹475.00₹250.00₹469.3010
Sep ’24₹396.45
₹346.20
-12.7%
19.2%₹475.00₹250.00₹470.1510
Aug ’24₹358.30
₹346.20
-3.4%
19.2%₹475.00₹250.00₹451.7510
Jul ’24₹366.65
₹331.40
-9.6%
19.0%₹475.00₹250.00₹430.8010
Jun ’24₹340.50
₹331.40
-2.7%
19.0%₹475.00₹250.00₹418.9510
May ’24₹307.60
₹371.73
+20.8%
29.7%₹630.00₹250.00₹450.0011
Apr ’24₹292.95
₹438.00
+49.5%
25.9%₹630.00₹295.00₹405.2510
Mar ’24₹314.15
₹470.00
+49.6%
28.2%₹735.00₹323.00₹409.8011
Feb ’24₹334.10
₹470.00
+40.7%
28.2%₹735.00₹323.00₹389.2511
Analyst Price Target
Consensus Narrative from 14 Analysts
₹526.50
Fair Value
10.9% overvalued intrinsic discount
14
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 03:31
End of Day Share Price 2025/01/31 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Laurus Labs Limited is covered by 22 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Nitin BhasinAmbit Capital
null nullAntique Stockbroking Ltd.